Novo Nordisk's Ozempic drug gets FDA OK for 2 mg dose to treat Type-2 Diabetes
Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.
Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added. In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Officials expected to offer 2nd booster shot for those over 50 years oldAs soon as Tuesday, the FDA could authorize COVID-19 booster shots for Americans over 50 years old, two officials familiar with the matter told ABC News, though the fourth shots are likely to be only offered and not formally recommended.
Read more »
FDA expected to OK 4th COVID-19 vaccine dose for adults over 50, UW doctor weighs inThe FDA is expected to give its authorization for a fourth COVID-19 vaccine dose for Americans 50 and older as early as Tuesday.
Read more »
The FDA is expected to approve a second COVID booster for people 50 and upThe FDA will likely authorize a secondary booster dose for adults 50 years and older this week.
Read more »
Diabetes Drug Metformin Linked to Birth Defects in BoysThe drug metformin, widely used to treat diabetes, may cause genital birth defects in the male children of men who take the medication, researchers have found.
Read more »
FDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Read more »